secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001213900-22-048141
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences reports Q2 2022 net loss of $8.9M; warns of insufficient working capital for 12 months
--------------------------------------------------------------------------------

- Net revenues Q2 2022 $4.3M, down 34% YoY from $6.5M; sequentially up 33% from Q1 2022 $3.2M.
- Net loss Q2 2022 $8.9M ($0.18/sh) vs net income $2.5M ($0.05/sh) in Q2 2021.
- Cash and equivalents $1.0M at June 30, 2022, down from $2.3M at Dec 31, 2021.
- Management says working capital insufficient for next 12 months without restructuring or new financing.
- In discussions to restructure indebtedness; awaiting Saudi marketing approval decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390022048141/0001213900-22-048141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390022048141/ea164264-8k_emmauslife.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-048141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer